Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey
- 26 May 2009
- journal article
- research article
- Published by BMJ in Journal of Medical Genetics
- Vol. 46 (8), 548-552
- https://doi.org/10.1136/jmg.2008.065904
Abstract
Background: Fabry disease is a rare X-linked lysosomal storage disorder characterised by severe multisystemic involvement that leads to major organ failure and premature death in affected men and women. Over the past 7 years, the Fabry Outcome Survey (FOS) has collected data on the natural history of Fabry disease, and the long-term efficacy and safety of enzyme-replacement therapy. This paper provides an update on the first analysis of FOS data. Design: Baseline data on clinical manifestations and causes of death in a cohort of 1453 patients (699 male, 754 female) from 19 countries worldwide were analysed. Causes of death of affected relatives were analysed separately. Results: The most frequently reported signs and symptoms of Fabry disease were neurological. Cardiac, ocular, gastrointestinal, dermatological, auditory and renal manifestations were also common. The principal causes of death among 181 affected relatives of patients in FOS (most of whom had died before 2001) were renal failure in males (42%) and cerebrovascular disease in females (25%). In contrast, of the 42 patients enrolled in FOS whose deaths were reported between 2001 and 2007, cardiac disease was the main cause of death in both male (34%) and female (57%) patients. Conclusion: These data suggest that the importance of renal disease as a cause of death in patients with Fabry disease is decreasing while the importance of cardiac disease is increasing. This pattern probably reflects improvements in the management of renal disease in patients with Fabry disease.Keywords
This publication has 25 references indexed in Scilit:
- Agalsidase Alfa and Kidney Dysfunction in Fabry DiseaseJournal of the American Society of Nephrology, 2009
- Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapyNephrology Dialysis Transplantation, 2009
- Agalsidase Alfa Slows the Decline in Renal Function in Patients with Fabry DiseaseAmerican Journal of Nephrology, 2008
- Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adultsNature Clinical Practice Nephrology, 2008
- Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry RegistryMolecular Genetics and Metabolism, 2007
- Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome surveyEuropean Heart Journal, 2007
- Enzyme replacement therapy with agalsidase alfa in children with Fabry diseaseActa Paediatrica, 2006
- High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*American Journal of Human Genetics, 2006
- Enzyme replacement therapy with agalsidase β improves cardiac involvement in Fabry's diseaseClinical Genetics, 2004
- Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous malesJournal of Medical Genetics, 2001